Vineti, a San Francisco, CA-based cell and gene therapy software and analytics company, closed raised $13.75M in Series A funding.
Backers included GE Ventures, Mayo Clinic Ventures and new investors DFJ and LifeForce Capital.
The company intends to use the funds to grow its team.
Co-founded by GE and the Mayo Clinic and led by Amy DuRoss, CEO, Heidi Hagen, chief strategy officer; Razmik Abnous, CTO; and Malek Faham, chief science officer, Vineti provides a commercial cloud-based platform that aims to improve patient access, accelerate life-saving treatment delivery, and promote safety and regulatory compliance for individualized cell therapies.
The platform integrates logistics, manufacturing and clinical data to improve product performance overall and enable faster, broader access for patients.